Home

Kilitch Drugs (india) Ltd PE Ratio

Image

Kilitch Drugs (India) Ltd

NSE: KILITCH

PE

32.5

Last updated on: Jan 15, 2025

Key Highlights

  • The P/E Ratio of Kilitch Drugs (India) Ltd is 32.5 as of 15 Jan 9.00 AM .
  • The P/E Ratio of Kilitch Drugs (India) Ltd changed from 147.7 on March 2020 to 42.9 on March 2024 . This represents a CAGR of -21.91% over 5 years.
  • The Latest Trading Price of Kilitch Drugs (India) Ltd is ₹ 332.9 as of 14 Jan 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Kilitch Drugs (India) Ltd

No data available

Company Fundamentals for Kilitch Drugs (India) Ltd

Image

Kilitch Drugs (India) Ltd

NSE: KILITCH

Share Price

₹ 332.9

17.90 (5.68%)

stock direction

Last updated on: Jan 14, 2025

Market Price of Kilitch Drugs (India) Ltd

1M

1Y

3Y

5Y

Monitoring Kilitch Drugs (India) Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
14 Jan 2025332.9
13 Jan 2025315
10 Jan 2025333.15
09 Jan 2025344.75
08 Jan 2025351.5
07 Jan 2025351.3
06 Jan 2025347.9
03 Jan 2025343.45
02 Jan 2025324.4
01 Jan 2025329.9

SWOT Analysis Of Kilitch Drugs (India) Ltd

Strength

4

che

Weakness

2

che

Opportunity

0

che

Threats

1

che

BlinkX Score for Kilitch Drugs (India) Ltd

Asset Value vs Market Value of Kilitch Drugs (India) Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Kilitch Drugs (India) Ltd535.38
Sun Pharmaceuticals Industries Ltd424382
Divis Laboratories Ltd159224
Cipla Ltd116943
Dr Reddys Laboratories Ltd111588

PE Ratio of Kilitch Drugs (India) Ltd Explained

``

535.38

Market cap

16

Earnings

32.5X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Kilitch Drugs (India) Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Kilitch Drugs (India) Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Kilitch Drugs (India) Ltd

No data available

* All values are in %

About Kilitch Drugs (India) Ltd

  • Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
  • Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
  • The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

Kilitch Drugs (India) Ltd News Hub

Kilitch Drugs (India) consolidated net profit declines 60.12% in the June 2024 quarter

Net profit of Kilitch Drugs (India) declined 60.12% to Rs 1.34 crore in the quarter ended June 2024

Read more

2024-08-09 00:00:00

Kilitch Drugs (India) to conduct board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 8 August 2024.

Read more

2024-08-02 00:00:00

Kilitch Drugs (India) to convene AGM

Kilitch Drugs (India) announced that the 32th Annual General Meeting (AGM) of the company will be he

Read more

2024-08-31 00:00:00

Kilitch Drugs (India) announces board meeting date

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 12 November 20

Read more

2024-11-05 00:00:00

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Kilitch Drugs (India) Ltd

What is the current PE Ratio of Kilitch Drugs (India) Ltd?

The Current PE Ratio of Kilitch Drugs (India) Ltd is 32.51 as on 15 Jan 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 15 Jan 2025.

What was the PE Ratio of Kilitch Drugs (India) Ltd last year?

The PE Ratio of Kilitch Drugs (India) Ltd was 20.8 last year, now the PE ratio is 32.51, showing a year-on-year growth of 56.3%.

What does the PE Ratio of Kilitch Drugs (India) Ltd indicate about its stock?

The PE Ratio of Kilitch Drugs (India) Ltd is 32.51. This ratio indicates that investors are willing to pay 32.51 times the earnings per share for each share of Kilitch Drugs (India) Ltd.

What is the PE Ratio Growth of Kilitch Drugs (India) Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Kilitch Drugs (India) Ltd grew by 56.3% whereas, the EPS ratio grew by 545.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions